Literature DB >> 16960113

Unique model of dormant infection for tuberculosis vaccine development.

Suely S Kashino1, Pamela Ovendale, Angelo Izzo, Antonio Campos-Neto.   

Abstract

Most individuals exposed to Mycobacterium tuberculosis become infected but hinder the infectious process in dormant foci, known as latent tuberculosis. This limited infection usually stimulates strong T-cell responses, which provide lifelong resistance to tuberculosis. However, latent tuberculosis is still poorly understood, particularly because of the lack of a reliable animal model of dormant infection. Here we show that inoculation of mice with a unique streptomycin-auxotrophic mutant of Mycobacterium tuberculosis recapitulates dormant infection. The mutant grows unimpaired in the presence of streptomycin and no longer grows but remains viable for long periods of time after substrate removal, shifting from the log growth phase to the latent stage, as indicated by augmented production of alpha-crystallin. Mice challenged with the mutant and inoculated with streptomycin for approximately 3 weeks developed a limited infection characterized by a low bacteriological burden and the presence of typical granulomas. After substrate withdrawal, the infection was hindered but few microorganisms remained viable (dormant) in the animals' tissues for at least 6 months. In addition, the animals developed both potent T-cell responses to M. tuberculosis antigens, such as early culture filtrate, Ag85B, and ESAT-6, and resistance to reinfection with virulent M. tuberculosis. Therefore, infection of mice or other animals (e.g., guinea pigs) with M. tuberculosis strain 18b constitutes a simple and attractive animal model for evaluation of antituberculosis vaccines in the context of an M. tuberculosis-presensitized host, a prevailing condition among humans in need of a vaccine.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960113      PMCID: PMC1563568          DOI: 10.1128/CVI.00120-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  41 in total

1.  Novel mutation in 16S rRNA associated with streptomycin dependence in Mycobacterium tuberculosis.

Authors:  N Honoré; G Marchal; S T Cole
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

2.  Effects of aminoguanidine on latent murine tuberculosis.

Authors:  J L Flynn; C A Scanga; K E Tanaka; J Chan
Journal:  J Immunol       Date:  1998-02-15       Impact factor: 5.422

3.  Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha -crystallin.

Authors:  D R Sherman; M Voskuil; D Schnappinger; R Liao; M I Harrell; G K Schoolnik
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-19       Impact factor: 11.205

4.  A mouse model of the recrudescence of latent tuberculosis in the elderly.

Authors:  I M Orme
Journal:  Am Rev Respir Dis       Date:  1988-03

5.  T-cell responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 in Brazilian tuberculosis patients.

Authors:  Fernando L L Cardoso; Paulo R Z Antas; Alexandre S Milagres; Annemieke Geluk; Kees L M C Franken; Eliane B Oliveira; Henrique C Teixeira; Susie A Nogueira; Euzenir N Sarno; Paul Klatser; Tom H M Ottenhoff; Elizabeth P Sampaio
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine.

Authors:  M Jackson; S W Phalen; M Lagranderie; D Ensergueix; P Chavarot; G Marchal; D N McMurray; B Gicquel; C Guilhot
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10.

Authors:  I Brock; M E Munk; A Kok-Jensen; P Andersen
Journal:  Int J Tuberc Lung Dis       Date:  2001-05       Impact factor: 2.373

8.  Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis.

Authors:  A D Roberts; M G Sonnenberg; D J Ordway; S K Furney; P J Brennan; J T Belisle; I M Orme
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

9.  Immunization of mice with mycobacterial culture filtrate proteins.

Authors:  R D Hubbard; C M Flory; F M Collins
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

10.  Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins.

Authors:  P Andersen
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more
  9 in total

1.  Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.

Authors:  Claudia Sala; Neeraj Dhar; Ruben C Hartkoorn; Ming Zhang; Young Hwan Ha; Patricia Schneider; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

2.  Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1β.

Authors:  Bibhuti B Mishra; Vijay A K Rathinam; Gregory W Martens; Amanda J Martinot; Hardy Kornfeld; Katherine A Fitzgerald; Christopher M Sassetti
Journal:  Nat Immunol       Date:  2012-11-18       Impact factor: 25.606

3.  Guinea pig model of Mycobacterium tuberculosis latent/dormant infection.

Authors:  Suely S Kashino; Danielle R Napolitano; Ziedonis Skobe; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2008-09-06       Impact factor: 2.700

4.  CD271(+) bone marrow mesenchymal stem cells may provide a niche for dormant Mycobacterium tuberculosis.

Authors:  Bikul Das; Suely S Kashino; Ista Pulu; Deepjyoti Kalita; Vijay Swami; Herman Yeger; Dean W Felsher; Antonio Campos-Neto
Journal:  Sci Transl Med       Date:  2013-01-30       Impact factor: 17.956

5.  Mycobacterium marinum causes a latent infection that can be reactivated by gamma irradiation in adult zebrafish.

Authors:  Mataleena Parikka; Milka M Hammarén; Sanna-Kaisa E Harjula; Nicholas J A Halfpenny; Kaisa E Oksanen; Marika J Lahtinen; Elina T Pajula; Antti Iivanainen; Marko Pesu; Mika Rämet
Journal:  PLoS Pathog       Date:  2012-09-27       Impact factor: 6.823

Review 6.  Current and novel approaches to vaccine development against tuberculosis.

Authors:  Mark J Cayabyab; Lilia Macovei; Antonio Campos-Neto
Journal:  Front Cell Infect Microbiol       Date:  2012-12-06       Impact factor: 5.293

7.  Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis.

Authors:  Bibhuti B Mishra; Rustin R Lovewell; Andrew J Olive; Guoliang Zhang; Wenfei Wang; Eliseo Eugenin; Clare M Smith; Jia Yao Phuah; Jarukit E Long; Michelle L Dubuke; Samantha G Palace; Jon D Goguen; Richard E Baker; Subhalaxmi Nambi; Rabinarayan Mishra; Matthew G Booty; Christina E Baer; Scott A Shaffer; Veronique Dartois; Beth A McCormick; Xinchun Chen; Christopher M Sassetti
Journal:  Nat Microbiol       Date:  2017-05-15       Impact factor: 17.745

Review 8.  Initiation of Post-Primary Tuberculosis of the Lungs: Exploring the Secret Role of Bone Marrow Derived Stem Cells.

Authors:  Lekhika Pathak; Bikul Das
Journal:  Front Immunol       Date:  2021-01-21       Impact factor: 7.561

9.  Genomic and transcriptomic analysis of the streptomycin-dependent Mycobacterium tuberculosis strain 18b.

Authors:  Andrej Benjak; Swapna Uplekar; Ming Zhang; Jérémie Piton; Stewart T Cole; Claudia Sala
Journal:  BMC Genomics       Date:  2016-03-05       Impact factor: 3.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.